Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Clin Nucl Med. 2023 Apr 1;48(4):335-336. doi: 10.1097/RLU.0000000000004537. Epub 2023 Jan 12.
We report the case of a 52-year-old man affected with a metastasized neuroendocrine tumor (G2) of the pancreas. After surgical removal, follow-up imaging 36 months later revealed somatostatin receptor-positive liver lesions. Because of disease progression under cold somatostatin analogs 6 months later, peptide receptor radionuclide therapy was performed, that induced complete remission (CR), supporting the notion that "hot" somatostatin analogs can achieve CR even in patients affected with pancreatic G2 neuroendocrine tumor. Of note, such cases exhibiting CR upon peptide receptor radionuclide therapy are extremely rare and further investigations may pool those exceptional treatment responders.
我们报告了一例 52 岁男性患有胰腺转移神经内分泌肿瘤（G2）的病例。手术后 36 个月的随访影像学检查显示生长抑素受体阳性的肝病变。由于 6 个月后冷生长抑素类似物治疗下疾病进展，进行了肽受体放射性核素治疗，诱导完全缓解（CR），这支持了“热”生长抑素类似物甚至可以在患有胰腺 G2 神经内分泌肿瘤的患者中实现 CR 的观点。值得注意的是，在肽受体放射性核素治疗后表现出 CR 的这种情况极为罕见，进一步的研究可能会汇集这些特殊的治疗反应者。
